Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2018 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are themselves doing and scaling — i.e., whether a substantial part of the forward account consists of reporting on the growth/expansion/ramp of specific customers, partners, payers, etc., that the company already supplies, such that the company's own coming volume is presented as a consequence of those parties' trajectories. Let me scan the transcript for such narration. Key candidates: - Aimovig: management talks about 12,000 prescribers, 100,000 patients started, payer approvals (70% approval rate), ESI win, Anthem, Kaiser. But this is about the company's own launch and selling effort, not about counterparties' own build-out trajectories. The payers are discussed as access wins, not as parties whose own expansion drives Amgen's volume. - Repatha: new NDC at lower list price to reduce out-of-pocket for Medicare Part D patients. This is about the company's own pricing action, not counterparty trajectories. - Biosimilars: KANJINTI and AMGEVITA launched in Europe. Management says "early days" and "so far so good" — but this is about the company's own launches, not about counterparties scaling. - Prolia: repeat injection rates, share gains — company's own performance. - KYPROLIS: label expansion, own strategy. - Parsabiv: uptake at dialysis providers — but this is described as the company's own selling effort ("we continue to see strong uptake"), not narrating the providers' own expansion plans. - Tezepelumab, omecamtiv mecarbil — pipeline, own programs. Is there any place where management narrates a counterparty's own ramp as the driver? The dialysis providers (Fresenius, DaVita) are mentioned for Parsabiv adoption, but not as a trajectory narrative. The payers for Aimovig are mentioned as access wins, not as scaling parties. The essence of the question: does management's forward account consist of reporting on somebody else's growth as the reason for its own? I don't see that. Management's account is about its own launches, its own pricing, its own pipeline, its own share gains. The counterparties mentioned (payers, dialysis providers, prescribers) are discussed in terms of Amgen's selling effort and access wins, not as parties whose own expansion drives Amgen's volume. Answer: NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.